The AI engine is offline (last seen Aug 12, 05:02 UTC). Scores are shown as of their timestamps; new theses and refreshes are queued and run the moment it returns.

Macro

Search catalysts, news stories, and pressures, or browse the trust-weighted news feed below.

Home tech energy finance healthcare defense industrial consumer communication utilities real estate raw materials
← back
healthcare · sector mood
2004
year mood +0.15 · -0.20 to +0.30 across 12 mo
Monthly mood
bearish −1 +1 bullish
-0.5 -0.25 0 +0.25 +0.5 Jan +0.30 Feb Mar Apr May Jun Jul Aug Sep Oct Nov -0.20 Dec
month values ▾
JanFebMarAprMayJunJulAugSepOctNovDec
+0.30+0.30+0.30+0.30+0.30+0.30+0.30+0.30+0.01-0.17-0.20-0.20

A solid year turned dark in September when Merck withdrew Vioxx over heart-attack and stroke risk, wiping out ~$30B of value and opening a liability wave that cast a safety-scrutiny cloud over the whole industry.

How this mood is scored ▾
Each day the model reads that day's news for the sector and asks, as someone who owns assets or makes their living in it: how am I feeling this month, and why? The month's mood is that running answer, tied to the specific events driving it (the story shown above). It leans on trusted, higher-impact reporting, and on the prior month when a month is quiet, so one loud headline can't swing it. The read updates daily through the month; once a month ends, its mood is locked. This year is read live from the news the pipeline actually collected (hover a bar for its story count). · last computed Jul 11, 2026
Top healthcare stories of 2004
Sep
Merck withdraws Vioxx over heart attack and stroke risk npr.org →

Merck & Co. voluntarily pulled its arthritis drug Vioxx from the global market due to an increased risk of heart attacks and strokes after 18 months of use, affecting 2 million patients. The FDA will review similar drugs Celebrex and Bextra, while investors may reassess pharmaceutical sector risks tied to drug safety and regulatory scrutiny.

Oct
Chiron's flu vaccine license suspended, halving US supply cidrap.umn.edu →

British regulators halted Chiron's flu vaccine production due to contamination, leading US authorities to block its use and cut the national supply by nearly half. With Aventis Pasteur now the sole supplier, the CDC has prioritized high-risk groups for vaccination, while warning against price gouging amid surging demand and limited availability.